Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Operating Leases (2019 - 2025)

Sunshine Biopharma's Operating Leases history spans 5 years, with the latest figure at $596785.0 for Q4 2025.

  • For Q4 2025, Operating Leases fell 19.86% year-over-year to $596785.0; the TTM value through Dec 2025 reached $596785.0, down 19.86%, while the annual FY2025 figure was $596785.0, 19.86% down from the prior year.
  • Operating Leases reached $596785.0 in Q4 2025 per SBFM's latest filing, down from $636708.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $744724.0 in Q4 2024 to a low of $440298.0 in Q3 2024.
  • Average Operating Leases over 4 years is $596466.0, with a median of $596850.0 recorded in 2023.
  • Peak YoY movement for Operating Leases: fell 22.44% in 2024, then surged 52.63% in 2025.
  • A 4-year view of Operating Leases shows it stood at $642232.0 in 2022, then fell by 16.07% to $539035.0 in 2023, then soared by 38.16% to $744724.0 in 2024, then decreased by 19.86% to $596785.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Operating Leases are $596785.0 (Q4 2025), $636708.0 (Q3 2025), and $706530.0 (Q2 2025).